Abstract
914P - Do patients (pts) with advanced nonseminomatous germ cell tumors (aNSGCT) and unfavorable time to normalization (TTN) of tumor markers benefit with prolongation of 1-st line chemotherapy (ChT)?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have